Liver receptor homolog-1 (LRH-1, NR5A2) is an orphan nuclear receptor that has an essential role in cancer progression, notably in breast cancer. Although its role in promoting cancer cell proliferation and migration is well documented, the molecular basis is not completely established. Here, we report that LRH-1 inhibition affects two-and three-dimensional cell proliferation of different types of breast cancer cells, including estrogen receptor α (ERα)-positive and triple-negative cells. This phenotype is accompanied by the upregulation of the cyclin-dependent kinase inhibitor CDKN1A (aka p21 CIP1/WAF1 ) in a p53-independent manner. Chromatin immunoprecipitation analysis shows that LRH-1 cooperates with FOXA1 and binds directly to CDKN1A promoter and a distal regulatory region found at − 62 kb from its transcriptional start sites, allowing repression of CDKN1A transcription. LRH-1 or FOXA1 depletion induces CDKN1A upregulation by removing histone deacetylase 2 from the promoter and distal regulatory elements and permitting histone acetylation in these regions. Analysis of breast cancer samples reveals that a high LRH-1 level is inversely correlated with CDKN1A expression in breast cancer patients and is associated with poor prognosis. This study reveals a novel mechanism of control of cell proliferation by LRH-1 regulating CDKN1A transcription in breast cancer cells, independent of ERα and p53 status. Targeting LRH-1 may provide an attractive prospect for treatment of tumors that are resistant to hormonal and targeted therapy.
INTRODUCTION
Breast cancer is the most common cancer in women, and its treatment depends on the type of cancer and its stage. Based on its molecular phenotype, breast cancers can be divided into luminal-and basal-like subtypes. 1 The luminal subtype is most common (460%), shows relatively good prognosis and is generally characterized by the expression of the estrogen receptor α (ERα, ESR1) and progesterone receptor (PR, PGR). ERα is a key target of breast cancer treatment. Patients with ERα-positive breast tumors have generally a better prognosis and can benefit from antihormonal therapy to prevent disease relapse. To block the ERα-mediated growth of these tumors, antiestrogen synthetic molecules have been developed to compete with estrogens for receptor binding. Although antiestrogen such as tamoxifen or fulvestrant/ICI182780 are beneficial to a large number of patients, close to 50% fail to respond to initial therapy (de novo resistance) or will develop resistance after prolonged antiestrogen treatment in spite of ERα presence. 2 Basal-like breast carcinomas represent 10-20% of breast cancer and are more aggressive and invasive tumors. Most of these tumors contain p53 mutations and are often referred to as triple-negative, because they do not express ER or PR hormonal receptors nor the human epidermal growth factor receptor 2 (HER2/neu) (ER-/PR-/HER2-). 1 Owing to their insensitivity to targeted therapy and only partial response to conventional chemotherapy, these cancers are associated with very poor prognosis. Thus, initial drug resistance or acquired drug resistance during prolonged treatment is a major problem limiting the clinical benefit of breast cancer therapy.
Liver receptor homolog-1 (LRH-1; NR5A2) is an orphan member of the nuclear receptor family that has important role in fertility and pregnancy by acting on the hypothalamus, ovary and endometrium to control ovulation and placentation. [3] [4] [5] LRH-1 is also essential during embryonic development for maintaining stem cell pluripotency. In adults, LRH-1 is highly expressed in tissues involved in digestive function such as liver, pancreas and intestine where it regulates cell proliferation and renewal, production and secretion of digestive enzymes and steroidogenic factors. [6] [7] [8] [9] Additionally, LRH-1 is a key mediator of metabolic homeostasis in the liver, regulating bile acid, lipid and glucose synthesis, storage and redistribution. 10, 11 Nonetheless, when overexpressed in these tissues, LRH-1 promotes both uncontrolled proliferation and tumorigenesis. 6, 7, 12, 13 Likewise, LRH-1 was found to be highly expressed in breast carcinomas, notably in invasive ductal carcinoma and ductal carcinoma in situ. 14, 15 In breast cancer cells, knockdown of endogenous LRH-1 inhibits tumor cell proliferation, migration and invasion. 14, 16, 17 A significant correlation has been observed between genes regulated by LRH-1 and those overexpressed in tumors associated with poor clinical prognosis. Moreover, LRH-1 is overexpressed in endocrineresistant breast cancer cells, 16 suggesting that LRH-1 could be involved in cancer progression.
A well-characterized mechanism of action for LRH-1 is its crosstalk with estrogen signaling in breast cancer cells in which its expression is controlled by estrogen. 14 Furthermore, LRH-1 regulates ERα expression and controls ERα target genes by cooperative binding with ERα at estrogen response elements. [18] [19] [20] LRH-1 is also expressed in adipose tissue and cancer-associated fibroblasts surrounding the tumor microenvironment where it controls cytochrome P450 aromatase expression (CYP19A1), the essential enzyme required for estrogen synthesis, thereby acting in a paracrine manner on neighboring tumor cells. 21, 22 Although LRH-1 action seems to be highly correlated with estrogen/ERα signaling, LRH-1 is also expressed in ERα-negative breast cancer cells, 17, 23 suggesting an important role of this receptor in hormone-independent cancers.
Here, we investigate the molecular action of LRH-1 in breast cancer cell proliferation. We show that LRH-1 knockdown affects two-(2D) and three-dimensional (3D) cell proliferation of several breast cancer cells, including ERα-positive and ERα-negative cells. The cyclin-dependent kinase inhibitor CDKN1A (p21 CIP1/WAF1 ) was found to be overexpressed following LRH-1 depletion, and it is significant that this occurs in a p53-independent manner. Moreover, we demonstrate that CDKN1A is a direct target of LRH-1 by showing its binding to the promoter and distal regulatory region found at − 62 kb from CDKN1A transcription start site (TSS). LRH-1 cooperates with FOXA1 and attenuates the expression of CDKN1A by the recruitment of histone deacetylase 2 (HDAC2). Finally, we determined the clinical implication of these results and showed that LRH-1 is inversely correlated with CDKN1A expression in breast cancer and is associated with poor prognosis.
Taken together, these findings reveal a novel and important role played by the nuclear receptor LRH-1 in the control of cell growth and establish LRH-1 as an attractive prospect for the development of new breast cancer therapy.
RESULTS

LRH-1 controls 2D and 3D breast cancer cells proliferation
To better understand LRH-1 molecular action, we first depleted its expression using a lentiviral-based short hairpin RNA (shRNA) in a panel of breast cancer cell lines expressing LRH-1, including ERαpositive MCF7 cells, their antiestrogen-resistant derivatives, LCC2 (tamoxifen-resistant) and LCC9 (tamoxifen/fulvestrant-resistant). 24 MCF7 cells that overexpress HER2 (MCF7/HER2) and the triplenegative (ER − /PR − /HER2 − ) MDA-MB-231 and BT-549 breast cancer cells received the same treatment (Figure 1a and Supplementary Figures S1-3 ). Although the LRH-1 shRNA (shLRH-1, no. 1) had only a partial effect, shLRH-1 nos 2 and 3 efficiently depleted LRH-1 at both mRNA (Supplementary Figure  S2 ) and protein levels ( Figure 1a ). We next tested the effect of LRH-1 knockdown on cell proliferation and observed a strong reduction of MCF7, LCC2 and LCC9 cell abundance with shLRH-1 nos 2 and 3 when compared with control shRNA (shCTL) ( Figure 1b ). Interestingly, LRH-1 knockdown considerably decreased cell proliferation of HER2-overexpressing MCF7 cells (Supplementary Figure S3 ), and also the ERα-negative breast cancer cells MDA-MB-231 and BT-549 ( Figure 1b ).
To provide more physiologically relevant conditions for tumor cell growth, we performed the same experiment with 3D culture system. Following lentiviral transduction, shLRH-1 and shCTL cells were dispensed in 3D culture plate to form hanging drops. MCF7, LCC2, LCC9 and BT-549 cells slowly aggregated in the bottom center of the droplet and produced monoculture spheroid after a few days. Spheroids were maintained over a period of 1 month. To evaluate cell viability and surface area of the spheroids, cells were stained with calcein AM. The LRH-1-depleted MCF7 cells presented a decrease of spheroid growth compared with control cells (Figure 1c ). More importantly, this effect was stronger in the endocrine-resistant LCC2, and LCC9 cells and the ERα-negative BT-549 cells, where LRH-1 knockdown decreased or, in some cases, inhibited completely spheroid growth (Figures 1c and d) . Taken together, these results show that LRH-1 controls cell proliferation independent of the ERα status of breast cancer cells and their sensitivity to hormonal therapy.
LRH-1 depletion induces cell-cycle arrest and CDKN1A gene expression in a p53-independent manner
To determine how LRH-1 depletion affects cell proliferation in breast cancer cells, we performed analysis of their cell-cycle distribution by fluorescent-activated cell sorting. LRH-1-depleted cells showed an~2 0% gain in the G1 phase, increasing from 55-65% in shCTL to 75-85% in shLRH-1 cells (Figure 2a ). Remarkably, the BT-549 cell line did not show, as others cell lines, a change in the number of cells in the G1 phase following LRH-1 knockdown. However, we observed an accumulation of cells in the G2/M phase of the cell cycle of 32% in the BT-549 shLRH-1 cells compared with 22% in the shCTL cells.
Moreover, we were surprised to observe that LRH-1-depleted breast cancer cells harbored a strong senescence-associated phenotype. These phenotypic alterations included cell-cycle arrest as shown in Figure 2a , morphological changes such as enlarged and flattened cellular shape, β-galactosidase activity and the occurrence of heterochromatin foci (senescence-associated heterochromatic foci) (Supplementary Figure S4) . To elucidate the molecular mechanism of the senescence-like growth arrest following LRH-1 knockdown, we focused our analysis on two well-recognized markers of senescence, the cyclin-dependent kinase inhibitor CDKN1A/p21 and CDKN2A/p16. LRH-1 depletion did not affect the level of CDKN2A in BT-549 cells carrying wildtype CDKN2A nor in MCF7, LCC2, LCC9 and MDA-MB-231 cells in which the CDKN2A locus is mutated or deleted (Supplementary Figure S5 ). Conversely, we observed that CDKN1A expression was upregulated in LRH-1-depleted MCF7, LCC2 and LCC9 cells as well as in HER2-overexpressing MCF7 and the triple-negative breast cancer cells ( Figure 2b and Supplementary Figures S3C and 6 ). Western blot analysis also confirmed CDKN1A upregulation at the protein level ( Figure 2c ).
To confirm that CDKN1A upregulation in LRH-1-depleted cells was not dependent on p53, we first determined its protein level in MCF7 cells following LRH-1 knockdown. We observed that the expression of p53 was not increased at the protein and mRNA levels ( Supplementary Figures S7A and D) . Furthermore, CDKN1A was induced in a p53-independent manner in MCF7 cells as well as in MDA-MB-231 and BT-549, two cell lines in which p53 is mutated and in which LRH-1 depletion also induced CDKN1A expression ( Figure 2b ). Additionally, FAIRE-qPCR (formaldehydeassisted isolation of regulatory elements-quantitative polymerase chain reaction) analysis in MCF7 cells showed a new region of open chromatin detected 2.2 kb upstream of the TSS of the CDKN1A gene following p53 activation by daunorubicin ( Supplementary Figure S7B , upper panel). Chromatin accessibility for the same p53 binding site was not affected by LRH-1 depletion (Supplementary Figure S7B , lower panel). Further arguing for a p53-independent action on CDKN1A, microarray data obtained in LRH-1-depleted MCF7 cells did not show the upregulation of other well-known p53 target genes (Supplementary Figure S7C ; Bianco et al. 16 ). These results were confirmed by qPCR of the ubiquitinprotein ligase MDM2 and the cell proliferation marker PCNA, neither of which displayed an increase in expression following LRH-1 knockdown (Supplementary Figure S7D ). Taken together, these data show that LRH-1 controls cell cycle by regulating the CDKN1A expression in a p53-independent manner, and suggest that targeting LRH-1 could be relevant for the treatment of breast cancer tumors regardless of their p53 status.
LRH-1 regulates CDKN1A expression through direct binding at a distal regulatory region and TSS. To elucidate whether LRH-1 effect is directly mediated on CDKN1A transcription, we performed chromatin immunoprecipitation (ChIP) using specific antibodies for LRH-1, specific chromatin marks and transcriptional factors. Remarkably, our previous LRH-1 ChIP-seq analysis revealed a distal regulatory element bound by LRH-1 at − 62kb from CDKN1A TSS (Figure 3a ; Bianco et al. 16 ). The presence of LRH-1 at the CDKN1A locus was validated by ChIP-qPCR at this distal element and TSS in the antiestrogen-sensitive MCF7 and antiestrogen-resistant LCC2 and LCC9 breast cancer cells, as well as in the triple-negative MDA-MB-231 and BT-549 cells (Figure 3b ). In line with our published LRH-1 cistrome characterization, the distal CDKN1A LRH-1 binding site was associated with strong FAIRE and H3K27ac signals that are specific chromatin signatures of transcriptional regulatory regions ( Figure 3a ). Furthermore, LRH-1 colocalized with the mediator subunit Med12 and RNA polymerase II (RNAPII), known to be specific marks for enhancers involved in long-range enhancerpromoter looping. 25, 26 To confirm this hypothesis, we used the RNAPII ChIA-PET (chromatin interaction analysis by paired-end tag sequencing) data obtained from MCF7 cells, 27 which allows the identification of 3D chromatin interactions involving a specific transcription factor at a genome-wide level. We showed that this distal site bound by LRH-1 is effectively involved in long-range interaction, notably by looping with CDKN1A promoter region (Figure 3a , lower panel). Altogether, these results show that LRH-1 regulates CDKN1A transcription through a distal regulatory element in breast cancer cells. 28 Because Forkhead motifs were enriched within LRH-1 binding sites in MCF7 cells (Figure 4a ), we speculated that FOXA1 may have a similar role for the binding of LRH-1. By comparing our LRH-1 ChIP-seq data with FOXA1 binding sites, 29 we found that 60% of LRH-1 binding sites are bound by FOXA1, revealing that LRH-1 signaling is highly, but not entirely mediated by FOXA1 ( Figure 4a ). More specifically, we found that FOXA1 colocalized with LRH-1 at the CDKN1A distal element and TSS region ( Figure 4b ). Enrichment for FOXA1 at these binding sites was confirmed by ChIP-qPCR, when compared with a negative control region ( Figure 4c) . Surprisingly, LRH-1 knockdown altered FOXA1 binding at this distal site without affecting its protein level (Figure 4d ). These results suggest a role for this pioneer factor in the regulation of CDKN1A. Accordingly, FOXA1 depletion using two different and efficient shRNA constructs also induced CDKN1A/p21 expression at mRNA and protein levels (Figures 4e and f). However, FOXA1 knockdown also decreased LRH-1 expression. Taken together, these results suggest that FOXA1 mediates LRH-1 signaling and expression to induce cellular proliferation by regulating CDKN1A expression.
LRH-1 depletion allows CDKN1A upregulation by removing HDAC2 and promoting histone acetylation To gain insight into how LRH-1 regulates CDKN1A expression, we performed ChIP analysis on specific chromatin marks and transcriptional factors on CDKN1A locus in LRH-1-depleted MCF7 cells. Figure 5a depicts the CDKN1A locus that includes the location of the − 62 kb element, and the TSS and the qPCR amplicons used in these experiments. As expected, there was an enrichment of LRH-1 binding at the distal regulatory element, whereas LRH-1 depletion reduced LRH-1 binding in this region (Figure 5b) . A small enrichment of LRH-1 was also observed at the TSS region, but this enrichment showed no significant change after LRH-1 depletion. LRH-1 knockdown did not affect chromatin opening as shown by FAIRE-qPCR. RNAPII was prebound to the TSS of CDKN1A, as previously shown in other studies, 30 and in the absence of LRH-1 significantly increased RNAPII binding. Moreover, H3K4me1, H3K4me3 and H3K27ac, specific marks of enhancers or promoters, [31] [32] [33] showed no marked changes in chromatin state after LRH-1 knockdown. However, in the absence of LRH-1, acetylated histone H3 and H4 marks were more enriched around the TSS, and, for H4panAc, enrichment was also observed at the distal regulatory site. This effect was accompanied by a decreased binding of the histone deacetylase HDAC2 at both the distal regulatory site and around the TSS (Figure 5b ). These results are consistent with an increase in histone acetylation, a modification that is permissive for CDKN1A gene transcription (Figures 5b and d) . Interestingly, FOXA1 depletion induced a similar pattern for HDAC2 binding (Figure 5c ).
Altogether, these data suggest that an LRH-1/FOXA1/HDAC2 complex modulates CDKN1A transcription through histone deacetylation, particularly in the region surrounding the TSS.
High LRH-1 and low CDKN1A levels are associated with poor prognosis in breast cancer patients To probe the pathological relevance of LRH-1 regulation of CDKN1A gene expression in breast cancer, we used the cBioPortal for Cancer Genomics tools 34, 35 to explore genomic alterations of LRH-1/NR5A2 and CDKN1A. We found alterations (amplification, mutation and mRNA expression levels) of LRH-1/NR5A2 in 13% and of CDKN1A in 5% of the breast-invasive carcinomas analyzed (Figure 6a ). Interestingly, these alterations occurred in mutual exclusivity. To further assess the potential role of these two genes 36 Expression of LRH-1/NR5A2 or CDKN1A alone did not influence the survival of patients. However, when we examined these genes together, our Kaplan-Meier analysis revealed that high LRH-1/NR5A2 expression associated with low CDKN1A expression decreased the probability of diseasefree survival (Figure 6b ). Altogether, these results show that LRH-1/ NR5A2 and CDKN1A expression levels could be used as biomarker to predict clinical outcome of breast cancer patients.
DISCUSSION
Targeting ERα by antiestrogens has been an important advance in the treatment of breast cancer. This notwithstanding, development of antiestrogen resistance is frequently observed following prolonged treatment. We showed in our previous work that LRH-1 is overexpressed in endocrine-resistant breast cancer cell lines. A significant correlation has been observed between genes regulated by LRH-1 in these cells and genes overexpressed in breast cancers that are associated with poor clinical prognosis. 16 Here, we provide evidence that LRH-1 is a critical factor of breast cancer cell proliferation, functioning by regulating gene expression of the cyclin-dependent kinase inhibitor CDKN1A.
Interestingly, these effects observed in the antiestrogenresponsive MCF7 cell line are also valid for the endocrineresistant MCF7/HER2, LCC2 and LCC9 cells, which are not able to respond to tamoxifen and/or fulvestrant therapy in spite of ERα presence. 2, 16, 37 In previous studies, LRH-1 expression has been positively correlated with ERα status in breast carcinomas. 14, 15 Although LRH-1 is also expressed in ERα-negative breast cancer cells, its precise mode of action was barely investigated in these cells. Importantly, here we demonstrate that LRH-1 controls cell proliferation in the triple-negative MDA-MB-231 and BT-549 cell lines. Altogether, these results suggest that LRH-1 have an important role in the aggressiveness and spread of hormoneindependent cancers. It will be interesting to explore the genomewide action of LRH-1 defining its cistrome and transcriptional program in an ERα-independent context. CCND1 and MYC are often overexpressed in endocrine-resistant tumor and were found to be downregulated in endocrineresistant cellular models following LRH-1 depletion. 2, 16 Thus, on the one hand, LRH-1 positively regulates important genes that promote cell proliferation and, on the other hand, it represses CDKN1A as shown here. CDKN1A is a cyclin-dependent kinase inhibitor that inactivates cyclin-cyclin-dependent kinase complexes involved in the transition of G1/S phase of the cell cycle. CDKN1A also contributes to the regulation of the G2/M-phase progression. 38, 39 Our data revealed that LRH-1 knockdown promotes both G1/S and G2/M cell-cycle arrest depending of the cell type. G2/M-phase growth arrest was observed more prominently in retinoblastoma protein-negative cells. 39 Interestingly, one of the defining characteristics of the BT-549 cell line is a defect of the tumor suppressor retinoblastoma protein, 40 and we have shown that this cell line displays G2/M growth arrest following LRH-1 depletion. This is in contrast with the other cell lines we tested where the arrest was observed in the G1 phase of the cell cycle.
In this study, we showed that LRH-1 knockdown increases CDKN1A expression in the p53-mutated MDA-MB-231 and BT-549 cell lines. The p53 tumor suppressor gene is a key factor in the positive regulation of CDKN1A, 38 but is often mutated or inactivated in human cancers, rendering therapeutic targeting of p53 non-effective and promoting aggressiveness of cancers. 41 Triple-negative breast cancers are currently treated with conventional chemotherapies owing to the lack of gene-targeted therapies. Nonetheless, more than 50% of these cancers present loss of or mutations in p53, rendering chemotherapy less effective. 1, 41 Our results suggest that targeting LRH-1 could be an interesting strategy to induce CDKN1A expression in a p53independent manner.
We have presented convincing evidence that LRH-1 directly regulates CDKN1A expression by binding to a site very distal to its TSS. Many studies on the regulation of CDKN1A by nuclear receptors, notably by ERα, androgen receptor or peroxisome proliferator-activated receptor-γ, have reported binding only at the proximal promoter via numerous Sp1 binding sites and hormone response elements. [42] [43] [44] This distal LRH-1 binding site displays the specific marks of active chromatin, as previously demonstrated, such as by FAIRE, H3K27ac, Med12 and RNAPII enrichment, suggesting a possible enhancer-promoter looping. This was confirmed with RNAPII ChIA-PET data showing the involvement of RNAPII in long-range interactions between this − 62 kb distal site and the CDKN1A promoter. These results bring new insights into the mechanism of CDKN1A transcription and reflect the importance of chromatin 3D organization in the regulation of gene expression. Further investigations are needed to determine the precise mechanism of how this long-range interaction is formed between these two regulatory regions.
Activation of nuclear receptors results in both induction and repression of gene transcription. For example, ERα-mediated gene repression involves active recruitment of repressive complexes, including corepressors and HDAC proteins. 45 Of note, many studies with regulators involved in this pathway have shown the implication of HDAC proteins in the negative regulation of CDKN1A transcriptional initiation at the proximal promoter. 46, 47 Mechanistically, we showed that distal LRH-1 binding attenuates CDKN1A expression by the recruitment or the stabilization of HDAC2 and through chromatin looping from the distal LRH-1 binding site to the CDKN1A proximal promoter (Figure 5d ). Acetylated histone lysine residues are recognized by bromodomain proteins. Deacetylation of chromatin at the CDKN1A promoter may interfere with the recruitment of bromodomain proteins such as Brd4, a positive regulatory component of transcriptional elongation complex. 48 Importantly, we found an association of FOXA1 with the distal LRH-1 binding site, suggesting a possible role for this pioneer factor in the targeting of LRH-1 in CDKN1A intergenic region. As observed for LRH-1, the depletion of FOXA1 also induces the expression of CDKN1A. These results are consistent with those showing that FOXA1 depletion decreases cell proliferation in breast cancer cells. 29 FOXA1 also has an important role in the targeting of ERα in MCF7 cells, 29 suggesting a pleiotropic role in targeting transcription factors to specific chromatin domains. It is essential to recognize that ERα-negative cancer cell models used in this study do not express FOXA1. It is possible that other Forkhead transcription factors such as FOXM1, notably expressed in MDA-MB-231, 49 In summary, this study establishes an important role played by the nuclear receptor LRH-1 in cell proliferation, by regulating the expression of cyclin-dependent kinase inhibitor CDKN1A in breast cancer cells regardless of ERα or p53 status. The development of specific antagonist targeting LRH-1 may be an attractive possibility for the treatment of tumors that are resistant to hormonal and targeted therapy. This study also suggests that LRH-1 and CDKN1A status might be additional and useful molecular prognostic markers in breast cancer in addition to the current ones. 
MATERIALS AND METHODS
shRNA lentiviral transduction
The shRNA against LRH-1 (sequences included in Supplementary Table S1 ) and FOXA1 50 were purchased from Open Biosystems (Thermo Scientific, Ottawa, ON, Canada) in the pLKO.1 vector. Breast cancer cells were transduced with shLRH-1 nos 1-3 or shCTL lentiviruses, obtained as described previously, 16, 51 and collected after 4 days of transduction for mRNA or protein extraction.
RNA analysis
Four days after lentiviral transduction with LRH-1 knockdown construct, total RNA was collected from breast cancer cells and analyzed as described previously. 51 For qPCR, 36B4 was used as an internal control. Primers used are listed in Supplementary Table S2 .
Western blotting
Cells were lysed in RIPA buffer. Proteins (30 μg-100 μg) were separated on 10 or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, transferred onto a nitrocellulose membrane and blotted for specific antibodies listed in Supplementary Table S4 .
Cell proliferation assays
For 2D cell proliferation assays, breast cancer cells were plated at a density of 10 000 cells per well in 48-well plates the day after lentiviral transduction and cell counting was performed every 3 days using TC20 Automated Cell Counter (Bio-Rad, Mississauga, ON, Canada). For 3D spheroid culture, MCF7, LCC2, LCC9 and BT-549 cells were grown in suspension in 45 μl of medium at a density of 2000 cells per drop in Perfecta 3D 96-well Hanging Drop Plate (3D Biomatrix, Tekniscience, Terrebonne, QC, Canada). Fifteen microliters of medium was removed every 2-3 days and replaced with 20 μl of fresh medium. For live cell staining, calcein AM (Life Technologies, Burlington, ON, Canada) was added at a final concentration of 3 μM on top of the spheroids for 30 min at 37 ºC. Spheroid growth was evaluated measuring surface area. Fluorescence images were taken and analyzed using the Leica DM IL microscope (Leica Microsystems, Concord, ON, Canada) and Infinity2 camera (Lumenera Corporation, Ottawa, ON, Canada) and the free open source CellProfiler (www.cellprofiler.org) and ImageJ software (www.rsb.info.nih.gov/ij/index.html).
Cell-cycle analysis and cellular senescence assays
Cell-cycle distribution was achieved by fluorescent-activated cell sorting as described previously. 51 For β-galactosidase staining, cells were fixed 8 days after shRNA lentiviral transduction in 3% formaldehyde for 5 min and incubated for 16 h at 37°C with staining solution containing 40 mM citric acid/sodium phosphate buffer, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride and 1 mg/ml X-gal. Images were acquired with the Leica DM IL microscope and Infinity2 camera. For senescence-associated heterochromatic foci detection, cells grown on coverslips were fixed in 4% formaldehyde for 30 min and stained with Hoechst. Images were acquired with the Olympus FV300 microscope (Olympus, Richmond Hill, ON, Canada) and CoolSNAP-Pro Camera (Photometrics, Tucson, AZ, USA).
ChIP and FAIRE assays, ChIP-seq data analysis and visualization
ChIP and FAIRE experiments were performed as described previously. 16 The antibodies and primers used are listed in Supplementary Tables S3 and  S4 . ChIP-seq data sets from MCF7 cells were obtained from database accession number GSE47027 for LRH-1, RNAPII, Med12 and FAIRE; 16 GSM832458 and GSM832459 for RNAPII ChIA-PET; 27 and E-MTAB-223 for FOXA1. 29 Aligned tags from ChIP-seq experiment were converted to WIG files by F-Seq 52 and visualized with IGV. 53 Motif enrichment was analyzed using HOMER 54 on the top 2000 enriched LRH-1 binding sites.
Survival and oncoprint analysis
Kaplan-Meier survival analysis was generated using BreastMark (http:// glados.ucd.ie/BreastMark/). 36 Each gene (NR5A2/LRH-1 and CDKN1A) was analyzed alone according to disease-free survival and then together with the inverse option for CDKN1A. OncoPrint showing NR5A2/LRH-1 and CDKN1A genomic alteration in breast-invasive carcinoma (The Cancer Genome Atlas) was created using the cBioPortal for Cancer Genomics. 34, 35 
